Lifetime Cost‐Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis

Documenti analoghi

• Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis
  di: Branislav V. Bajkin, et al.
  Pubblicazione: (2026)
• Multicentre Retrospective and Prospective Analysis of Data on Emicizumab and Factor VIII Prophylaxis in Children With Severe Haemophilia A: Egypt‐Compare Study
  di: Tamer Hassan, et al.
  Pubblicazione: (2026)
• Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype
  di: Nuchanun Kessakorn, et al.
  Pubblicazione: (2024)
• TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab
  di: Kagehiro Amano, et al.
  Pubblicazione: (2025)
• Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors
  di: Midori Shima, et al.
  Pubblicazione: (2025)